Stiolto Respimat (olodaterol/tiotropium FDC) / Boehringer Ingelheim - LARVOL DELTA

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.

New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Hanmi Pharm to sell 3 Boehringer COPD inhalers in Korea, including Spiriva and Vahelva (Korea Biomedical Review) - "Hanmi said domestic distribution and promotion will begin shortly."

Commercial • Chronic Obstructive Pulmonary Disease

TUSSIVE SYNCOPE IN A PATIENT WITH INFLUENZA B AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (CHEST 2025) - "After testing positive for Influenza B, he was prescribed oseltamivir. He was advised to continue his COPD medications, including triple therapy (fluticasone, umeclidinium, vilanterol) and ipratropium/albuterol inhalers...He returned to his primary care provider 3 days later, who started him on amoxicillin-clavulanate, benzonatate, and prednisone...He was treated with budesonide and albuterol nebulizers, tiotropium/olodaterol inhaler, IV methylprednisolone, diphenhydramine plus hydrocodone, and azithromycin... Patients with influenza and comorbidities such as COPD and coronary artery disease should be assessed for signs of syncope, particularly in those with prolonged and intense coughing episodes. Additionally, patient education and close monitoring are crucial to reduce the risk of fall-related injuries."

Clinical • Cardiovascular • Chronic Cough • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Cough • Gastroenterology • Gastroesophageal Reflux Disease • Hypertension • Hypotension • Immunology • Infectious Disease • Influenza • Musculoskeletal Diseases • Obstructive Sleep Apnea • Orthopedics • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL. (PubMed, Int J Chron Obstruct Pulmon Dis) - "TIO/OLO initiators incurred lower pharmacy costs related to COPD and/or pneumonia than FF/UMEC/VI initiators. These results support treatment recommendations of reserving inhaled corticosteroids for frequent exacerbators and patients with elevated eosinophil counts."

Clinical • Clinical data • Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease[ACHIEVE] (ERS 2025) - P=N/A | "Tiotropium/olodaterol therapy offers potential benefits in improving exercise capacity in patients with COPD, particularly in those with lower baseline exercise capacity and pulmonary hyperinflation (NCT04994574)."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

The effect of tiotropium/olodaterol on lung, right ventricular function and serum troponin I levels in patients with moderate chronic obstructive pulmonary disease (ERS 2025) - "COPD treatment with TIO/OLO not only improves lung function but also might have a positive effect on right ventricular strain and reduce serum troponin I levels. Due to cardiovascular involvement in COPD early use of dual bronchodilation is very important."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

ANTES B+ Clinical Trial (clinicaltrials.gov) - P4 | N=48 | Terminated | Sponsor: Fundacio Privada Mon Clinic Barcelona | N=1028 ➔ 48 | Trial completion date: Sep 2025 ➔ Jan 2025 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2025 ➔ Jan 2025; Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Effect of fixed-dose tiotropium/olodaterol combined therapy on exercise-related outcome measures in individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis. (PubMed, Expert Rev Respir Med) - "Tio/Olo 5/5 μg FDC compared to Tio 5 μg or placebo may improve exercise tolerance and lung function, but not physical activity levels in COPD. The systematic review protocol is registered on PROSPERO (International Prospective Register of Systematic Reviews): number CRD42024598553."

Clinical • Journal • Retrospective data • Review • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Rationale and Design of an Exploratory, Randomized, Open-Label, Multicenter Clinical Trial to Investigate the Efficacy of Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist on Heart Failure Complicated by Chronic Obstructive Pulmonary Disease (COPD-HF Trial). (PubMed, Circ Rep) - "The participants are randomly assigned (1 : 1) to the LAMA/LABA (tiotropium+olodaterol FDC (fixed-dose combination) 5/5 ug) group (once a day, 2 inhalations) or non-pharmacological treatments for COPD as a control group...The primary endpoint is the change in plasma B-type natriuretic peptide levels from the baseline to the end of this study (12 weeks). The COPD-HF trial will investigate the efficacy of LAMA/LABA on HF in patients with COPD and CHF."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment-Naive Patients with COPD in the US. (PubMed, Int J Chron Obstruct Pulmon Dis) - P=N/A | "These results support treatment recommendations for LAMA+LABA as initial maintenance therapy. ClinicalTrials.gov identifier - NCT05169424."

Clinical • HEOR • Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Comparative effectiveness of olodaterol/tiotropium and vilanterol/umeclidinium among COPD patients: a high-dimensional propensity score matched new user cohort study in a US Medicare population. (PubMed, Expert Rev Respir Med) - "The adjusted hazard ratio of the time to first COPD exacerbation was 0.948 (95% Confidence interval: 0.813-1.105) for individuals initiating OLO/TIO versus VI/UMEC. We did not find a statistically significant difference between the OLO/TIO and VI/UMEC new users in terms of time to first severe exacerbation among Medicare COPD patients aged 65 or older."

HEOR • Journal • Medicare • Reimbursement • US reimbursement • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of RCTs. (PubMed, BMC Pulm Med) - "This systematic review and meta-analysis concludes that UMEC and VI combinations are an efficacious treatment option for symptomatic COPD patients."

Clinical • Journal • Retrospective data • Review • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

First Step in COPD – Journey with Vahelva (KATRDIC 2024) - "The inhaler device is important in COPD as many patients cannot reach the required peak inspiratory flow (PIF) for the respective inhalers or have critical errors. Soft mist inhalers such as the Respimat (that delivers tiotropium and olodaterol) combinations can deliver the drug irrespective of the PIF and recent studies will be presented."

Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Benefit of dual bronchodilator therapy on exacerbations in former and current smokers with chronic obstructive pulmonary disease in real-world clinical practice: a multicenter validation study (TOReTO). (PubMed, Respir Res) - "The three fixed-dose combinations of LABA/LAMA showed no difference in reducing exacerbations in former smokers but did show differences in current smokers. This trend has clinical significance, and future research will be conducted to control influencing variables to validate this point. However, due to the non-randomized study design, these findings should be interpreted with caution."

Journal • Real-world • Real-world evidence • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

BRONCHIECTASIS AND POTENTIAL BENEFIT OF MUCOSAL VACCINE (CHEST 2024) - "The last infectious exacerbation was on January 2023 treated with ciprofloxacin 500 mgs bid for 2 weeks...We starting management based on dual bronchodilation (Tiotropium + Olodaterol), mucolytic (erdosteine) and immunotherapy with MV130, 2 sublingual shots OD for three months...By November 2023 she visited emergency department due to a new recurrence treated with amoxicillin/clavulanate... Clinical trials are needed to clear expectations of the mucosal vaccines in the bronchiectasis field."

Bronchiectasis • Chronic Cough • Chronic Obstructive Pulmonary Disease • Cough • Immunology • Infectious Disease • Otorhinolaryngology • Pneumonia • Pulmonary Disease • Respiratory Diseases

The effect of tiotropium/olodaterol fixed-dose combination on cardiac function in patients with newly diagnosed moderate-to-severe chronic obstructive pulmonary disease (ERS 2024) - "COPD treatment with TIO/OLO shows benefit in reducing air-trapping and improving cardiac function as measured by CI. As COPD patients have a higher risk for cardiovascular events, our study data emphasizes the importance of dual bronchodilation in patients with moderate-to-severe COPD."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison table: Inhaled drugs for treatment of COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tobacco Cessation

Dynamic chest radiographic evaluation of the effects of tiotropium/olodaterol combination therapy in chronic obstructive pulmonary disease: the EMBODY study protocol for an open-label, prospective, single-centre, non-controlled, comparative study. (PubMed, BMJ Open Respir Res) - "The results of this trial will be published in a peer-reviewed journal. jRCTs032210543."

Clinical • Clinical protocol • Combination therapy • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients (PRNewswire) - "Boehringer Ingelheim's new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company's inhalers is now available. The program applies to all Boehringer Ingelheim inhalers, including: Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol. Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray. Spiriva HandiHaler (tiotropium bromide inhalation powder). Spiriva Respimat 1.25 mcg (tiotropium bromide) Inhalation Spray. Spiriva Respimat 2.5 mcg (tiotropium bromide) Inhalation Spray. Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray. Striverdi Respimat (olodaterol) Inhalation Spray."

Pricing • Asthma • Chronic Obstructive Pulmonary Disease

Systemic Manifestations of COPD and the Impact of Dual Bronchodilation with Tiotropium/Olodaterol on Cardiac Function and Autonomic Integrity. (PubMed, J Clin Med) - "Hs-CRP and IL-22 might be beneficial in determining the intensity of systemic inflammation in COPD. Further research with a larger cohort is needed to enhance the initial results of this study."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CRP • IL22

Fluticasone Furoate/Umeclidinium/Vilanterol Vs Open Triple Therapy for Treating Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) from a Brazilian Public Healthcare Perspective: A Budget Impact Analysis (ISPOR 2024) - " Using a 5-year budget impact analysis (BIA), we evaluated the financial impact of the progressive switch from multiple inhalers triple therapy available at SUS (LABA/LAMA = tiotropium/olodaterol (TIO/OLO) or umeclidinium/vilanterol (UMEC/VI) plus ICS = budesonide (BUD) or beclomethasone (BECL)) to single inhaler triple therapy with FF/UMEC/VI... This study suggests a better allocation of resources with equivalent therapeutic gain paralleled with adherence benefits for eligible patients with COPD."

HEOR • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

ANTES B+ Clinical Trial (clinicaltrials.gov) - P4 | N=1028 | Recruiting | Sponsor: Fundacio Privada Mon Clinic Barcelona | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

ANTES B+ Clinical Trial (clinicaltrials.gov) - P4 | N=1028 | Not yet recruiting | Sponsor: Fundacio Privada Mon Clinic Barcelona

New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "Higher pharmacy costs partially offset lower healthcare costs. Program participants showed improved COPD medication adherence and persistence compared to nonparticipants."

Adherence • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases